Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDER executive

This article was originally published in The Tan Sheet

Executive Summary

Scott Furness on Oct. 28 moved to director of the Division of Nonprescription Regulation Development in FDA's Center for Drug Evaluation and Research from working as a team leader in the Office of Generic Drugs, Division of Chemistry II, where he joined the agency seven and a half years ago as a primary chemistry reviewer, CDER says. Furness, who has a Ph.D. in synthetic organic chemistry, progressed to a senior regulatory review chemist at OGD before becoming a team leader in 2004. Prior to coming to FDA, he was an NIH postdoctoral fellow in the National Institute of Diabetes and Digestive and Kidney Diseases' Laboratory of Medicinal Chemistry, where he conducted research on the design, synthesis, and pharmacological evaluation of molecules directed at various central and peripheral drug receptors...

You may also be interested in...

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts